SCHEMBL23542286

SCHEMBL23542286

O=C(CCCSc1nc2c(c(=O)[nH]1)CCCC2)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.80

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MMP9 P14780 1/20 0.80
▸ TP53 P04637 1/20 0.58
▸ MAPT P10636 7/20 0.58
▸ POLB P06746 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ ALDH1A1 P00352 3/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ HPGD P15428 5/20 0.54
▸ LMNA P02545 2/20 0.54
▸ USP2 O75604 1/20 0.54
▸ TSHR P16473 1/20 0.51
▸ GAA P10253 1/20 0.50
▸ TNKS O95271 1/20 0.49
▸ PARP1 P09874 1/20 0.49
▸ WNT3A P56704 1/20 0.49
▸ TNKS2 Q9H2K2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20510185 0.89 MMP9 (1.00) MMP9MAPTPOLBL3MBTL1ALDH1A1
SCHEMBL23542308 0.89 MMP9 (0.69) MMP9TP53MAPTPOLBL3MBTL1
SCHEMBL23542284 0.88 MMP9 (0.83) MMP9TP53MAPTPOLBL3MBTL1
SCHEMBL23542288 0.88 MMP9 (0.76) MMP9TP53MAPTPOLBL3MBTL1
SCHEMBL27397735 0.87 MMP9 (0.81) MMP9MAPTPOLBL3MBTL1ALDH1A1
SCHEMBL27397754 0.87 MMP9 (0.81) MMP9MAPTPOLBL3MBTL1ALDH1A1
SCHEMBL23542282 0.87 MMP9 (0.81) MMP9MAPTPOLBL3MBTL1ALDH1A1
SCHEMBL20510321 0.87 MMP9 (0.81) MMP9MAPTPOLBL3MBTL1ALDH1A1
SCHEMBL23542280 0.86 MMP9 (0.74) MMP9TP53MAPTPOLBL3MBTL1
SCHEMBL23542279 0.83 MMP9 (0.81) MMP9TP53MAPTPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018003-B2 Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-06-25 — — US disclosed
US-20210309616-A1 SUBSTITUTED QUINAZOLINES AS MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2021-10-07 — — US disclosed
US-11040947-B2 Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2021-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018003-B2 Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors MMP9, MMP7, MMP11 MMP9 1/4885TP53 864/4885MAPT 422/4885
US-20210309616-A1 SUBSTITUTED QUINAZOLINES AS MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS MMP2, MMP9, MMP10 MMP9 2/4885TP53 903/4885MAPT 4268/4885
US-11040947-B2 Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors MMP2, CBR3, NR4A3 MMP9 14/4885TP53 4643/4885MAPT 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback